查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2046176

代謝紊亂治療市場－全球產業規模、佔有率、趨勢、機會和預測：按疾病類型、治療方法、地區和競爭格局分類，2021-2031年

Metabolic Disorders Therapeutics Market - Global Industry Size, Share, Trends, Opportunity & Forecast, Segmented By Disease Type, By Therapy Type, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球代謝紊亂治療市場預計將從 2025 年的 748.1 億美元大幅成長至 2031 年的 1,168.8 億美元，複合年成長率為 7.72%。

該市場涵蓋了旨在治療和控制擾亂正常代謝過程的疾病（例如糖尿病、肥胖症和溶小體儲積症）的多種藥物干預措施。其根本原因是全球慢性代謝疾病負擔日益加重，而這主要是由人口老化和久坐不動的生活方式所驅動的。國際糖尿病聯盟 (IDF) 預測，到 2025 年，全球約有 5.89 億 20 至 79 歲的成年人將患有糖尿病，凸顯了治療這些疾病的迫切需求。儘管需求強勁，但藥物研發的高昂成本和嚴格的監管核准流程從根本上阻礙了市場成長，常常導致新治療方法的商業化進程延遲，並限制了市場准入，尤其是在發展中地區。

市場概覽
預測期 2027-2031
市場規模：2025年 748.1億美元
市場規模：2031年 1168.8億美元
複合年成長率：2026-2031年 7.72%
成長最快的細分市場 糖尿病
最大的市場 北美洲

市場促進因素

代謝紊亂全球市場擴張的主要促進因素是久坐不動的生活方式和不健康飲食習慣的日益普遍。這些因素導致肥胖症和第2型糖尿病等慢性疾病顯著增加，對長期藥物治療產生了持續的需求。根據世界衛生組織（WHO）於2024年3月在《採血針上發布的《全球肥胖趨勢分析》數據，2022年全球肥胖人口超過10億，凸顯了有效體重管理療法的迫切需求。同時，專注於新型療法的強大研發開發平臺也顯著推動了市場發展。製藥公司正在增加對生物製藥和先進腸促胰島素促效劑的投資，這些藥物與傳統治療方法相比具有更高的療效和便利性。近期上市的代謝藥物取得的商業性成功凸顯了這項創新，諾和諾德公司報告稱，其糖尿病和肥胖症治療業務的銷售額成長了38%，在2023年達到2151億丹麥克朗。世界肥胖聯盟預測，到2035年，全球超重和肥胖造成的經濟損失預計將達到4.32兆美元，這些疾病的廣泛經濟影響正在推動進一步的投資。

市場挑戰

由於藥物研發固有的巨額資金需求和嚴格的法規結構，全球代謝紊亂治療市場正面臨許多挑戰。開發針對複雜代謝疾病的新藥通常需要巨額資本投入和漫長的研發週期，且臨床試驗失敗的風險很高。這種不穩定的環境阻礙了製藥公司對高風險創新治療方法的研發，可能導致先進治療方法研發管線停滯不前，並阻礙了滿足日益成長的全球需求所需的多樣化治療方案的快速推出。此外，為了彌補巨額研發成本，製藥公司通常會將新療法定價過高，這種財務負擔直接影響市場准入和銷售量成長，限制了醫療預算有限的發展中地區的藥物供應。歐洲製藥商協會聯合會 (EFPIA) 2024 年的預測凸顯了這一投資規模之龐大，該預測表明，僅歐洲以研發為基礎的製藥行業就投入了約 550 億歐元用於研發，這凸顯了全球擴張和商業化面臨的經濟障礙。

市場趨勢

代謝紊亂治療領域正經歷變革性的趨勢，尤其是針對特異性異構體體代謝路徑活化劑的研發，正在重塑代謝功能障礙相關性脂肪性肝炎（MASH）的治療模式。這些新型療法針對特定受體，例如甲狀腺激素受體BETA，透過減少肝纖維化和毒性，同時避免與廣譜荷爾蒙療法相關的全身性副作用，填補了重要的治療空白。根據Madrigal Pharmaceuticals公司報道，這項突破已於2024年3月獲得FDA加速核准，Rezdiffra（resmethirome）的上市為中重度肝纖維化的非肝硬化性MASH患者樹立了至關重要的新標準。同時，口服生物製劑和小分子製劑正成為治療方向，旨在從侵入性注射轉向更便捷、更容易患者接受的片劑。這一趨勢優先考慮擴充性的給藥方式，從而顯著提高患者對長期慢性病管理方案的依從性。這種新一代療法的可行性得到了早期臨床研究令人鼓舞的結果的支持。例如，羅氏公司正在研發的口服GLP-1受體促效劑CT-996，在2024年7月進行的一項I期臨床試驗中，僅四周治療後，肥胖患者的平均體重就減輕了7.3%，這凸顯了非注射代謝療法的巨大潛力。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：代謝紊亂治療藥物的全球市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 疾病類型（溶小體儲積症、糖尿病、肥胖、遺傳代謝疾病、高膽固醇症、其他）
    • 治療方法（酵素替代療法、細胞移植、小分子藥物療法、基材減少療法、基因療法、藥物療法）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美代謝紊亂治療藥物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲代謝紊亂治療藥物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區代謝失調治療藥物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東與非洲代謝紊亂治療藥物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲代謝紊亂治療藥物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章 全球代謝紊亂治療市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Novo Nordisk A/S
  • Eli Lilly and Company
  • Takeda Pharmaceutical Company Limited
  • Sanofi SA
  • Merck KGaA
  • AstraZeneca PLC
  • AbbVie Inc.
  • Johnson & Johnson Services, Inc
  • Amgen Inc.
  • BioMarin International Limited

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 17532

The Global Metabolic Disorders Therapeutics Market is projected for substantial growth, expanding from USD 74.81 Billion in 2025 to USD 116.88 Billion by 2031, at a Compound Annual Growth Rate of 7.72%. This market encompasses a broad spectrum of pharmaceutical interventions designed to treat and manage conditions that disrupt normal bodily metabolism, including diabetes, obesity, and lysosomal storage diseases. Its fundamental support stems from the escalating global burden of chronic metabolic conditions, largely driven by aging populations and increasingly sedentary lifestyles. The critical need for these therapeutics is underscored by statistics such as the International Diabetes Federation's projection that approximately 589 million adults aged 20 to 79 will be living with diabetes worldwide in 2025. Despite this robust demand, the market's growth is inherently challenged by the high costs associated with drug development and stringent regulatory approval processes, which frequently delay the commercialization of new treatments and limit market access, especially in developing regions.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 74.81 Billion
Market Size 2031USD 116.88 Billion
CAGR 2026-20317.72%
Fastest Growing SegmentDiabetes
Largest MarketNorth America

Market Driver

The primary catalyst for the expansion of the Global Metabolic Disorders Therapeutics Market is the increasing prevalence of sedentary lifestyles and unhealthy dietary habits, which have led to a significant rise in chronic conditions like obesity and type 2 diabetes, creating a sustained need for long-term pharmacological management. Data from the World Health Organization's 'Lancet Analysis of Global Obesity Trends' in March 2024 indicates that over 1 billion people globally were living with obesity in 2022, emphasizing the urgent demand for effective weight management therapies. Concurrently, the market is significantly propelled by robust research and development pipelines focusing on novel therapeutics. Pharmaceutical entities are increasingly investing in biologics and advanced incretin mimetics, which offer superior efficacy and convenience compared to traditional treatments. The commercial success of recently launched metabolic agents validates this innovation, with Novo Nordisk reporting a 38% increase in sales within its Diabetes and Obesity care division, reaching DKK 215.1 billion in 2023. The broader economic impact of these conditions further incentivizes investment, as the global cost of overweight and obesity is projected by the World Obesity Federation to reach USD 4.32 trillion by 2035.

Market Challenge

The expansion of the Global Metabolic Disorders Therapeutics Market faces significant impediments due to the substantial financial requirements and stringent regulatory frameworks inherent in drug development. Developing novel pharmaceutical interventions for complex metabolic conditions necessitates immense capital investment and prolonged timelines, often with a high risk of failure during clinical trials. This precarious environment discourages manufacturers from pursuing high-risk innovative therapies, potentially leading to a stagnation in the pipeline for advanced treatments and hindering the rapid introduction of diverse therapeutic options needed to meet escalating global demand. Furthermore, the financial burden directly affects market accessibility and volume growth, as companies often price new therapeutics at premium levels to recover massive research expenditures, thereby restricting availability in developing regions where healthcare budgets are limited. The magnitude of this investment intensity is highlighted by the European Federation of Pharmaceutical Industries and Associations' 2024 estimate that the research-based pharmaceutical industry invested approximately 55 billion Euros in R&D in Europe alone, underscoring the economic hurdles to global scalability and commercialization.

Market Trends

The metabolic disorders therapeutics sector is experiencing transformative trends, notably the development of isoform-specific metabolic pathway activators that are reshaping the treatment of metabolic dysfunction-associated steatohepatitis (MASH). These novel therapeutics target specific receptors, such as the thyroid hormone receptor-beta, to reduce liver fibrosis and toxicity without the systemic adverse effects associated with broader hormonal treatments, addressing a critical gap in care. This breakthrough was formally validated by the accelerated FDA approval of Rezdiffra (resmetirom) in March 2024, as reported by Madrigal Pharmaceuticals, establishing a pivotal new standard for noncirrhotic MASH with moderate to advanced liver fibrosis. Simultaneously, there is a definitive shift toward oral biologics and small molecule formulations, aiming to replace invasive injectable regimens with convenient, patient-friendly tablets. This trend prioritizes scalable delivery methods that significantly enhance adherence to long-term chronic disease management protocols. The viability of this next-generation approach is evidenced by promising early-stage clinical successes, such as Roche's investigational oral GLP-1 receptor agonist CT-996, which achieved a mean weight loss of 7.3% in participants with obesity after just four weeks of treatment in Phase I trials in July 2024, underscoring the potent potential of non-injectable metabolic therapies.

Key Market Players

  • Novo Nordisk A/S
  • Eli Lilly and Company
  • Takeda Pharmaceutical Company Limited
  • Sanofi SA
  • Merck KGaA
  • AstraZeneca PLC
  • AbbVie Inc.
  • Johnson & Johnson Services, Inc
  • Amgen Inc.
  • BioMarin International Limited

Report Scope

In this report, the Global Metabolic Disorders Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Metabolic Disorders Therapeutics Market, By Disease Type

  • Lysosomal Storage Diseases
  • Diabetes
  • Obesity
  • Inherited Metabolic Disorders
  • Hypercholesterolemia
  • Others

Metabolic Disorders Therapeutics Market, By Therapy Type

  • Enzyme Replacement Therapy
  • Cellular Transplantation
  • Small Molecule Based Therapy
  • Substrate Reduction Therapy
  • Gene Therapy
  • Drug Therapy

Metabolic Disorders Therapeutics Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Metabolic Disorders Therapeutics Market.

Available Customizations:

Global Metabolic Disorders Therapeutics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Metabolic Disorders Therapeutics Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Disease Type (Lysosomal Storage Diseases, Diabetes, Obesity, Inherited Metabolic Disorders, Hypercholesterolemia, Others)
    • 5.2.2. By Therapy Type (Enzyme Replacement Therapy, Cellular Transplantation, Small Molecule Based Therapy, Substrate Reduction Therapy, Gene Therapy, Drug Therapy)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Metabolic Disorders Therapeutics Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Disease Type
    • 6.2.2. By Therapy Type
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Metabolic Disorders Therapeutics Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Disease Type
        • 6.3.1.2.2. By Therapy Type
    • 6.3.2. Canada Metabolic Disorders Therapeutics Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Disease Type
        • 6.3.2.2.2. By Therapy Type
    • 6.3.3. Mexico Metabolic Disorders Therapeutics Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Disease Type
        • 6.3.3.2.2. By Therapy Type

7. Europe Metabolic Disorders Therapeutics Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Disease Type
    • 7.2.2. By Therapy Type
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Metabolic Disorders Therapeutics Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Disease Type
        • 7.3.1.2.2. By Therapy Type
    • 7.3.2. France Metabolic Disorders Therapeutics Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Disease Type
        • 7.3.2.2.2. By Therapy Type
    • 7.3.3. United Kingdom Metabolic Disorders Therapeutics Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Disease Type
        • 7.3.3.2.2. By Therapy Type
    • 7.3.4. Italy Metabolic Disorders Therapeutics Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Disease Type
        • 7.3.4.2.2. By Therapy Type
    • 7.3.5. Spain Metabolic Disorders Therapeutics Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Disease Type
        • 7.3.5.2.2. By Therapy Type

8. Asia Pacific Metabolic Disorders Therapeutics Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Disease Type
    • 8.2.2. By Therapy Type
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Metabolic Disorders Therapeutics Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Disease Type
        • 8.3.1.2.2. By Therapy Type
    • 8.3.2. India Metabolic Disorders Therapeutics Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Disease Type
        • 8.3.2.2.2. By Therapy Type
    • 8.3.3. Japan Metabolic Disorders Therapeutics Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Disease Type
        • 8.3.3.2.2. By Therapy Type
    • 8.3.4. South Korea Metabolic Disorders Therapeutics Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Disease Type
        • 8.3.4.2.2. By Therapy Type
    • 8.3.5. Australia Metabolic Disorders Therapeutics Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Disease Type
        • 8.3.5.2.2. By Therapy Type

9. Middle East & Africa Metabolic Disorders Therapeutics Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Disease Type
    • 9.2.2. By Therapy Type
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Metabolic Disorders Therapeutics Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Disease Type
        • 9.3.1.2.2. By Therapy Type
    • 9.3.2. UAE Metabolic Disorders Therapeutics Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Disease Type
        • 9.3.2.2.2. By Therapy Type
    • 9.3.3. South Africa Metabolic Disorders Therapeutics Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Disease Type
        • 9.3.3.2.2. By Therapy Type

10. South America Metabolic Disorders Therapeutics Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Disease Type
    • 10.2.2. By Therapy Type
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Metabolic Disorders Therapeutics Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Disease Type
        • 10.3.1.2.2. By Therapy Type
    • 10.3.2. Colombia Metabolic Disorders Therapeutics Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Disease Type
        • 10.3.2.2.2. By Therapy Type
    • 10.3.3. Argentina Metabolic Disorders Therapeutics Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Disease Type
        • 10.3.3.2.2. By Therapy Type

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Metabolic Disorders Therapeutics Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Novo Nordisk A/S
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Eli Lilly and Company
  • 15.3. Takeda Pharmaceutical Company Limited
  • 15.4. Sanofi SA
  • 15.5. Merck KGaA
  • 15.6. AstraZeneca PLC
  • 15.7. AbbVie Inc.
  • 15.8. Johnson & Johnson Services, Inc
  • 15.9. Amgen Inc.
  • 15.10. BioMarin International Limited

16. Strategic Recommendations

17. About Us & Disclaimer